ClinicalTrials.gg
WithdrawnNCT04073433Updated Oct 31, 2024

Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers (MT-2)

A Phase 1 interventional study of Midomafetamine HCl and Therapy in Psychological Effects of Study Drug, sponsored by Lykos Therapeutics. Withdrawn. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-31.

Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 1, Interventional, and Basic science

Why this study was withdrawn
Funding

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to study MDMA-assisted therapy in healthy volunteers and provide training of therapists. The main question it aims to answer is:

Does MDMA-assisted therapy result in personal and professional benefits?

Participants will have a non-drug preparatory session prior to each experimental session and an integrative session after each experimental session.

Read the detailed description

The Phase 1, randomized, placebo-controlled study MT1 was designed to collect safety and quantitative data on mood, psychological symptoms, personality traits, and interpersonal closeness in therapists learning to conduct MDMA-assisted psychotherapy or MDMA research among 120 healthy volunteers. The MT1 study was also designed to expand the knowledge of therapists training to conduct MDMA-assisted psychotherapy research. In the MT1 study, several participants submitted optional written narratives with impressions that participating in MDMA-assisted psychotherapy helped them professionally and personally.

This Phase 1, open-label, multi-site research study is designed to build upon the MT1 study to further assess the psychological effects and safety of manualized MDMA-assisted psychotherapy, while supporting the expansion of knowledge for treatment providers who are learning to conduct MDMA-assisted psychotherapy or MDMA research. This study is intended to look further into the personal and professional benefits spontaneously reported in narratives to the site team from the MT1 study participants. This will be done by collecting changes in self-compassion, burnout, professional quality of life, psychological inflexibility, and mood using validated measures in a larger sample of treatment providers, allowing for effect size calculations.

02

Conditions studied

  • Psychological Effects of Study Drug

Keywords

  • Mood
  • Subjective Effects
  • MDMA
03

In context

Lead sponsor

Lykos Therapeutics is the lead sponsor of 28 studies on the registry; 1 is open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are learning to conduct MDMA-assisted psychotherapy or MDMA research through the MDMA Therapy Training Program
  • Are at least 18 years old
  • Are fluent in speaking and reading the predominantly used or recognized language of the study site
  • Are able to swallow pills
  • Must provide a contact (relative, spouse, close friend or other caregiver) who is willing and able to be reached by the investigator in the event of an emergency or if the participant is unreachable
  • Must agree to inform the investigators within 48 hours if any medical conditions occur or medical procedures are planned
  • If of , must have a negative pregnancy test at study entry and prior to the Experimental Session, and must agree to use adequate through 10 days after the Experimental Session
  • If nursing, must be willing to dispose of breastmilk from dosing through 5 days after each Experimental Session
  • Must not participate in any other interventional clinical trials during the duration of the study
  • Must agree to not operate a vehicle for at least 24 hours after initial drug administration.
  • Must have transportation available after the Experimental Session and through the following day, for traveling back for the Integrative Session.
  • Must commit to medication dosing, therapy, and study procedures
  • Are willing to be contacted via telephone for all necessary telephone contacts.

Exclusion criteria

Exclusion Criteria:

  • Are not able to give adequate
  • Have uncontrolled hypertension
  • Have a marked baseline prolongation of /QTc interval (e.g., repeated demonstration of a QTc interval >450 milliseconds [ms] in males and >460 ms in females corrected by Bazett's formula)
  • Have a history of additional risk factors for Torsade de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
  • Have evidence or history of significant medical disorders
  • Have symptomatic liver disease
  • Have history of hyponatremia or hyperthermia
  • Weigh less than 45 kilograms (kg)
  • Are pregnant, or are of and are not practicing an effective means of
  • Have any current problematic patterns of alcohol or other substance use
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    MDMA-assisted therapy

    One session of MDMA-assisted therapy with a dose of 120 mg midomafetamine HCl and optional supplemental dose of 60 mg 1.5 to 2 hours later

    Drug: Midomafetamine HCl · Behavioral: Therapy

Interventions

  • 120 mg midomafetamine HCl

    Also known as: 3,4-methylenedioxymethamphetamine, MDMA, midomafetamine, MDMA HCl

  • BehavioralTherapy

    Non-directive therapy conducted during MDMA-assisted therapy session

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Self Compassion Scale (SCS) total score

    Self Compassion Scale (SCS) total score, a 26-item self-report measure of self-compassion

    Time frame: 9 weeks post-enrollment

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2024; primary completion for Dec 2025, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2019
First posted
Aug 29, 2019
StartEst.
Dec 2024
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Oct 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04073433
Lead sponsor
Lykos Therapeutics
Responsible party
Sponsor
First posted
Aug 29, 2019
Start date
Dec 2024 (estimated)
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Oct 31, 2024

Study contacts

Marcela Ot'alora
principal investigator · Private Practice

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine

Start the discussion